India, March 20 -- Natco Pharma Ltd. is set to launch the generic version of Ozempic at Rs.1,290 per month, underscoring the incoming price war for weight-loss drugs in India as the patent for key ingredient semaglutide expires.

Natco received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the generic drug. The approval covers both multi-dose vials and pen devices and was based on a clinical comparison study. Natco holds the distinction of being the first company to offer Semaglutide in a vial dosage form, specifically utilizing multi-dose vials equipped with customised syringes.

This is a developing story. More to come.

Published by HT Digital Content Services with perm...